The latest news from academia, regulators
research labs and other things of interest
Posted: Aug 29, 2012
pSivida CEO to discuss sustained delivery and nanotechnology in ophthalmology
(Nanowerk News) pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that Dr. Paul Ashton, President and CEO, has been invited to participate as a distinguished speaker at the Drug Delivery Technologies & Formulation Conference taking place on September 5-6 in Zurich Switzerland. Dr. Ashton’s topic is: “Eye Opening: Sustained Delivery and Nanotechnology in Ophthalmology.”
Dr. Ashton’s talk will focus on strategies and opportunities in delivery of ophthalmic drugs, many of which must be injected directly into the eye frequently, often monthly, for the duration of a patient’s life. His talk will focus on methods for enhanced topical delivery, long term intraocular delivery and novel surgical approaches. pSivida most recently announced a fully funded technology evaluation agreement with a leading global biopharmaceutical company to evaluate pSivida’s Tethadur™ protein/antibody delivery technology in the field of ophthalmology. Tethadur™ is an application of pSivida’s BioSilicon™ technology platform designed to provide sustained delivery of large biologic molecules, including proteins, antibodies and peptides.
The conference is designed to provide education, communication and networking opportunities for both scientific and business leaders engaged in drug delivery and formulation and includes speakers from academia, biotech and industry to discuss current and new strategies to succeed in this evolving area.
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
Check out these other trending stories on Nanowerk: